Forum Diabetologicum - Issue 2/2020
87
Niekoľko slov úvodom
prof. MUDr. Marián Mokáň, DrSc., Frcp Edin
Editorial
91
Heart failure at the time of “diabetes epidemic“
Eva Gon Alvesová
95
Pathophysiological aspects of chronic heart failure
Andrej Dukát, Juraj Payer, Ján Gajdošík, Valentín Szabó, Fedor Šimko
98
Chronic heart failure: a minimum for diabetologist
Eva Gon Alvesová
104
SGLT2 inhibitors in the treatment of diabetes mellitus
Peter Jackuliak, Magdaléna Kovářová, Juraj Payer
110
Use of glucometers in the care of patients with diabetes mellitus
Dana Prídavková, Udovít Šutarík, Peter Galajda, Marián Mokáň
115
Gliflozins and heart: Analyses of EMPRISE study
Marián Mokáň, Peter Galajda
121
Gliflozins and kidney: Analyses of CREDENCE study
Marián Mokáň, Peter Galajda
125
Liečba inhibítormi SGLT2 u pacientov so srdcovým zlyhávaním: Čo priniesla štúdia DAPA-HF pre kardiovaskulárnu diabetológiu?
Andrej Dukát, Milan Kriška, Juraj Payer
128
Relationship between overweight and obesity with the development of cardiovascular diseases
Ján Murín, Udovít Gašpar
132
Autodidaktický test hodnotený kreditmi ARS CME
Dana Prídavková
Forum Diabetologicum
Most read in this issue
- SGLT2 inhibitors in the treatment of diabetes mellitus
- Liečba inhibítormi SGLT2 u pacientov so srdcovým zlyhávaním: Čo priniesla štúdia DAPA-HF pre kardiovaskulárnu diabetológiu?
- Pathophysiological aspects of chronic heart failure
- Gliflozins and heart: Analyses of EMPRISE study